Alnylam Pharmaceuticals ALNY Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.17B+96.4% | $1.1B+84.9% | $1.25B+149% | $773.69M+17.3% | $594.19M+20.2% | ||
| $207.52M+196% | $267.72M+161% | $197.23M+141% | $142.03M+111% | $70.18M+28.5% | ||
| $959.66M+83.1% | $829.31M+69.1% | $1.05B+151% | $631.66M+6.6% | $524.01M+19.2% | ||
| 82.2%-6.0pp | 75.6%-7.1pp | 84.2%+0.6pp | 81.6%-8.2pp | 88.2%-0.8pp | ||
| $364.87M+37.6% | $372.22M+24.0% | $358.81M+32.4% | $323.62M+10.0% | $265.12M+1.6% | ||
| $322.55M+34.4% | $325.37M+10.2% | $322.08M+45.7% | $323.31M+30.2% | $239.95M+13.8% | ||
| $898.54M+56.0% | $965.32M+38.2% | $881.04M+52.5% | $789.89M+29.2% | $576.11M+7.1% | ||
| $268.64M+1,386% | $131.72M+225% | $367.98M+578% | -$16.2M-133% | $18.08M+142% | ||
| 23%+20.0pp | 12%+29.7pp | 29.5%+44.8pp | -2.1%-9.5pp | 3%+11.8pp | ||
| $69.29M+18.8% | $65.4M+67.8% | $44.4M+29.2% | $40.25M+21.0% | $58.31M+65.4% | ||
| $26.6M-7.2% | $26.63M-14.1% | $28.68M-10.8% | $27.49M-5.8% | $28.67M-3.3% | ||
| -$46.98M-130% | -$45.46M+48.8% | -$129.01M-306% | -$19.16M+68.0% | -$20.45M-1.5% | ||
| $221.65M+9,460% | $86.26M+144% | $238.97M+320% | -$35.36M-217% | -$2.37M+96.3% | ||
| $15.66M-1.4% | —— | -$12.12M-517% | $30.92M+440% | $15.88M+576% | ||
| $205.99M+1,229% | $111.54M+233% | $251.08M+325% | -$66.28M-292% | -$18.25M+72.3% | ||
| 17.6%+20.7pp | 10.2%+24.3pp | 20.1%+42.4pp | -8.6%-6.0pp | -3.1%+10.3pp | ||
| $1.51+1,179% | $0.82+226% | $1.84+311% | -$0.51-292% | -$0.14+73.1% | ||
| $1.55+1,207% | $0.84+229% | $1.91+320% | -$0.51-292% | -$0.14+73.1% | ||
| 138.2M+6.6% | 134.7M+5.5% | 137.3M+6.8% | 130.6M+3.1% | 129.7M+2.8% | ||
| 132.9M+2.5% | 131M+2.6% | 131.4M+2.2% | 130.6M+3.1% | 129.7M+2.8% | ||
| $3.6M+320% | $0-100% | $2.92M-25.5% | $924K-34.0% | $858K-92.4% | ||
| $9.19M+152% | $1.3M-18.0% | $5.52M— | $431K— | $3.65M+62.8% | ||
| $201.19M+1,047% | $113.22M+221% | $259.26M+355% | -$58.71M-139% | -$21.25M+69.4% | ||
| $9.31M-3.4% | -$27.17M+74.7% | $5.6M+3,534% | $9.74M+2,763% | $9.64M+2,023% | ||
| $13.55M-5.9% | $13.51M-4.7% | $13.8M-1.3% | $13.94M-7.1% | $14.41M+6.6% | ||
| $2.37M-20.2% | —— | $1.28M-72.3% | —— | $2.97M+49.4% | ||
| $110.42M+1,385% | —— | $399.86M+978% | $136.91M+1,520% | $7.43M+1,913% | ||
| -$1.63M+94.0% | $0+100% | -$12.54M-301% | -$13.08M+93.2% | -$27.32M+4.3% | ||
| $3.32M+153% | —— | -$4.98M+16.0% | -$11.14M-64.0% | -$6.22M-28,150% | ||
| $6.32M-80.7% | $70.99M+381% | $20.74M+151% | $0+100% | $32.77M-56.6% | ||
| $64.2M-6.9% | $113.32M+819% | $23.89M+48.0% | $12.57M+54.1% | $68.93M+123% | ||
| $15.71M-65.9% | —— | -$448.35M-536% | $51.76M-60.6% | $46.08M+59.4% | ||
| -$25.54M-122% | $0+100% | $501.11M+1,757% | -$141.38M— | $113.77M+268% | ||
| $70.5M+159% | $163.56M+273% | $325.11M+644% | $155.73M+25.4% | -$120.31M-47.6% | ||
| -$3.65M-455% | $0+100% | $1.13M-87.5% | -$343K+52.8% | $1.03M+129% | ||
| -$4.3M-147% | $76.56M+195% | -$74.15M-151% | -$6.4M+88.5% | $9.19M+163% | ||
| $2.99M+115% | —— | —— | -$18.51M-57.1% | -$19.35M-197% | ||
| $261.63M-34.9% | $235.91M-51.5% | $207.97M-51.7% | $459.56M+54.4% | $401.64M-4.4% | ||
| $21.83M+143% | $23.29M+156% | $12.14M+190% | $14.29M+78.3% | $8.97M-30.9% | ||
| $13.16M-73.3% | $41.7M+14.9% | $77.74M-28.0% | $81.22M-38.8% | $49.37M+90.9% | ||
| $1.17B+96.4% | $1.1B+84.9% | $1.25B+149% | $773.69M+17.3% | $594.19M+20.2% | ||
| $70.15M+23.7% | $71.63M-21.8% | $108.21M+136% | $111.68M+25.1% | $56.71M+25.1% | ||
| $282.19M+769% | $145.22M+260% | $381.79M+707% | -$2.26M-104% | $32.48M+209% | ||
| 24.2%+18.7pp | 13.2%+28.6pp | 30.6%+43.1pp | -0.3%-9.9pp | 5.5%+11.5pp | ||
| $268.64M+1,386% | $131.72M+225% | $367.98M+578% | -$16.2M-133% | $18.08M+142% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
- Is Alnylam Pharmaceuticals profitable?
- Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
- What are Alnylam Pharmaceuticals's profit margins?
- Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
- What is Alnylam Pharmaceuticals's earnings per share?
- Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
- Where does Alnylam Pharmaceuticals's income statement data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
